Key result
Deuterium-labelled levobupivacaine is pharmacokinetically equivalent to unlabelled levobupivacaine (mean AUC ratio 1.02; 90% CI 1.00-1.04), enabling single-experiment absorption kinetics studies.
Population
8 volunteers (18-32 yr) and 15 surgical patients (23-85 yr)
Design
Other
Follow-up
up to 24 hours
Authors
Loading...
Permits single-experiment levobupivacaine PK studies; leaves open validation in broader clinical cohorts.
Effect estimate: Mean ratio 1.02 (95% CI 1.00-1.04)
D3-levobupivacaine is pharmacokinetically equivalent to unlabelled levobupivacaine and can be used to study its absorption and disposition kinetics in a single experiment.
Simon et al. (2004) studied Surgical patients (n=23). Deuterium-labelled levobupivacaine vs. Unlabelled levobupivacaine was evaluated on Ratio of the normalized areas under the curve of unlabelled and deuterium-labelled levobupivacaine (Mean ratio 1.02, 95% CI 1.00-1.04). Deuterium-labelled levobupivacaine is pharmacokinetically equivalent to unlabelled levobupivacaine (mean AUC ratio 1.02; 90% CI 1.00-1.04), enabling single-experiment absorption kinetics studies.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: